Filter Your Search

Collaboration with new pharma company paves the way for new NF treatments

Sep 25, 2017, Posted in Collaborations, Latest News, NF1, Science

SpringWorks Therapeutics, a Pfizer-conceived, mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, launched today with news of promising investigational therapies, including one for neurofibromatosis.  The Children’s Tumor Foundation is collaborating with this new company to connect the NF community with these much-needed therapies.

The 10th Anniversary Spectacular ‘Dancing with Our Stars’ Gala Crosses the Million Dollar Mark After a Decade of Dancing Towards a Cure

Sep 20, 2017, Posted in Community, Fundraiser, Galas, Latest News

This Year's Annual Little Rock Affair Raises $185,000 for NF Research and NF Camp

On September 7, 2017, Arkansas celebrities showed off their dance moves as they competed for the coveted mirror ball trophy at the 10th Anniversary Spectacular ‘Dancing with Our Stars’ Gala. Months of rehearsals with local dance instructors culminated in a one-time performance that raises money to fund critical neurofibromatosis (NF) research, supports local NF clinics, and sends Arkansas teens to NF Camp.

Stories of NF: Kaiden D.

Sep 18, 2017, Posted in NF Hero, NF1

Did you know that the name Kaiden means fighter or warrior? Even though I am only 9, I have been a fighter my entire life. On April 25, 2016, I had to have my leg amputated due to complications with NF. Losing my leg was very hard for me and everyone in my family. We knew that once the surgery took place, things would never be the same again.

Stories of NF: Andrea

Sep 12, 2017, Posted in NF Hero, NF1

NF1 has been impacting my life since I can remember. I had an optic pathway glioma in my right optic nerve which, when I was younger, pushed my right eye in a weird shape and position in my face (now prosthetic).

Advocacy Update

Sep 11, 2017, Posted in Advocacy

Today, the Senate is expected to begin consideration of S. 1519, the FY 2018 National Defense Authorization Act (NDAA).  As reported by the Senate Armed Services Committee, S. 1519 would have negative impacts on U.S. Department of Defense medical research programs.  The Children’s Tumor Foundation has actively and continuously engaged for the past months in many avenues of bipartisan advocacy to nullify these specific provisions in the legislation, working with the Foundation’s Capitol Hill allies, the Defense Health Research Consortium, and other stakeholders to ensure no impact to the Department of Defense medical research programs.